<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629745</url>
  </required_header>
  <id_info>
    <org_study_id>AALL12B6</org_study_id>
    <secondary_id>COG-AALL12B6</secondary_id>
    <secondary_id>NCI-2012-01981</secondary_id>
    <nct_id>NCT01629745</nct_id>
  </id_info>
  <brief_title>Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial</brief_title>
  <official_title>Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Testing for minimal residual disease in blood samples from patients with acute
      lymphoblastic leukemia may help doctors plan better treatment.

      PURPOSE: This research trial studies a genetic test in detecting minimal residual disease in
      samples from younger patients registered on COG-AALL08B1 trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Assess the feasibility of minimal residual disease (MRD) determination in pediatric
           B-lineage acute lymphoblastic leukemia (ALL) using deep sequencing of the immunoglobulin
           heavy chain locus.

      OUTLINE: Archived blood and tumor tissue samples are analyzed for MDR using deep sequencing
      of immunoglobulin heavy chain locus. MDR quantification results are then compared with the
      flow cytometry reference methods used in COG studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of deep sequencing of the immunoglobulin heavy chain locus in determining MRD in B-lineage ALL</measure>
  </primary_outcome>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Samples from patients registered on the Children Oncology Group (COG - AALL08B1)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Samples from patients registered on the Children Oncology Group (COG)-AALL08B1
             protocol and stored in the Hematopathology Laboratory at the University of Washington

               -  Pretreatment and after induction therapy samples

        PATIENT CHARACTERISTICS:

          -  Not specified

        PRIOR CONCURRENT THERAPY:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brent Wood, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Cancer Care Alliance</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Heavy Chains</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

